Generics and biosimilars

The Statista dossier
  • Detailed references
  • Editorially prepared
  • Download as PDF / PPT

Statista dossier about generic drugs and biosimilars

This dossier presents graphs and tables about the global generic drug industry and market. It also includes a chapter about biosimilars, complex, almost identical copies of biological drugs, which like generic drugs, have the potential for significant drug spending reductions.

Table of contents

  • 1. Global overview
    • Pharmaceutical market: worldwide revenue 2001-2018

    • Total worldwide generic prescription drug revenue 2010-2024

    • Global generic prescription drug revenues as share of prescribed revenue 2010-2024

    • Patent expiration risks for total worldwide prescription drug revenue 2010-2024

  • 2. Top companies
    • Revenues of leading global generics manufacturers 2016

    • Teva Pharmaceutical Industries' generic revenues by region 2016-2018

    • Novartis revenue 2014-2018 by segment

    • Pfizer's revenue by segment 2014-2018

  • 3. U.S. market
    • Brand and generic prescription medication revenue in the U.S. 2006-2016

    • U.S. brand and generic prescription drug revenue 2005-2016

    • Spending change on branded and generic medicines in the U.S. 2013-2017

    • Unbranded generics revenue top corporations in U.S. 2016-2017

    • Unbranded generics market share top corporations in U.S. 2016-2017

    • Top U.S. pharma products by prescriptions 2016

  • 4. Patent expiration
    • Projected sales at risk due to patent expiry 2009-2022

    • Top pharma companies by sales loss due to patent loss until 2018

    • Forecast of new brand and LOE impact on growth of developed pharma markets 2018-2022

    • Top branded biologic drugs in the U.S. that will go generic by 2028

    • Time from brand drug launch to generic patent challenges U.S. 1995-2014

    • Comparison of pre-expiry and generic price for drugs U.S. 2015

  • 5. Savings
    • Savings through generic drug usage in the U.S. 2008-2017

    • Total savings of top generic drugs in U.S. 2017

    • Saving of U.S. costs through generic pharmaceuticals by therapy 2017

    • Savings through generic drug usage in the U.S., by age group 2017

    • Savings through generic drug usage in the U.S., by payer 2017

    • Percentage savings through generic drug usage in the U.S. by payer 2017

    • Savings through generic drug usage in the U.S., by age group share 2017

  • 6. Biosimilars
    • Cumulative potential biosimilars market in EU5 countries and the U.S. 2016-2020

    • Country-wise biosimilar pipelines number in development worldwide 2017

    • Reduction in U.S. direct spending on originator biologics as of 2018

    • Share of filgrastim sales attributable to Neupogen or biosimilars US 2015-2017

    • Share of insuline glargine sales Lantus vs. biosimilar US 2015-2017

    • Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020

    • Physician office payment for biosimilars in Medicare Part B in 2018

More than 7,500
companies
trust
Statista
Recommended studies and dossiers
Show more
Recent studies and dossiers
You may also be interested in...
Statista is a great source of knowledge, and pretty helpful to manage the daily work.

Christof Baron about Statista CEO, MindShare Germany

Any more questions?

Get in touch with us quickly and easily.
We are happy to help!